BVT Aktienanleihe SNW 12.03.2025/ DE000VD06A46 /
5/24/2024 7:53:22 PM | Chg.-0.360 | Bid8:26:21 AM | Ask8:26:21 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
100.940EUR | -0.36% | 101.080 Bid Size: 5,000 |
104.580 Ask Size: 5,000 |
SANOFI SA INHABER ... | 87.79 EUR | 3/12/2025 | Call |
GlobeNewswire
7:00 AM
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire
5/21
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire
5/20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
5/20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
5/20
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire
5/13
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
5/13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
5/13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
5/10
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire
5/8
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/7
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
5/2
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...